ArticleThe Korean journal of internal medicine2011
Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease.
Article in The Korean journal of internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of Clofazimine in Treatment ofFrontiers in medicine · 2021Pooled it
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- The use of dual β-lactams to restore susceptibility ofJAC-antimicrobial resistance · 2024Article
- Epidemiological Characteristics of Nontuberculous Mycobacterial Pulmonary Disease in South Korea: A Meta-analysis of Individual Participant Data.Tuberculosis and respiratory diseases · 2024Article
- Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment ofFrontiers in pharmacology · 2021Article
- Quantitative analysis ofClinical proteomics · 2019Article
- Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea.The Korean journal of internal medicine · 2017Article
- Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin.Journal of fish diseases · 2017Article
- Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.Journal of pharmaceutical health care and sciences · 2015Article
- Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.Antimicrobial agents and chemotherapy · 2015Article
- Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.Tuberculosis and respiratory diseases · 2014Review
- The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease.BMC infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few studies have evaluated the treatment outcome of MAC pulmonary disease in Korea.
methodsThe efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42 patients treated for more than 6 months between January 2005 and December 2008. All patients were treated with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients.
resultsAmong the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months; IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs. 54.5%, p = 0.038).
conclusionsThe combined regimen including clarithromycin was effective against MAC pulmonary disease. High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.